Published online before print August 24, 2006, doi: 10.1161/01.STR.0000239696.61545.4b
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2006;37:2521.)
© 2006 American Heart Association, Inc.
Original Contributions |
Proof-of-Principle Phase II MRI Studies in Stroke
Sample Size Estimates From Dichotomous and Continuous Data
From the Department of Neurology, Royal Melbourne Hospital and University of Melbourne, Parkville, Australia.
Correspondence to Geoffrey A. Donnan, National Stroke Research Institute, Austin Health, University of Melbourne, 300 Waterdale Rd, Heidelberg Heights, Victoria 3081, Australia. E-mail gdonnan{at}unimelb.edu.au, or Stephen M. Davis, Department of Neurology, Royal Melbourne Hospital and University of Melbourne, Parkville, Victoria 3054, Australia. E-mail stephen.davis@mh.org.au
Background and Purpose— Since the failure of a number of phase III trials of neuroprotection in ischemic stroke, the need for smaller phase II studies with MRI surrogates has emerged. There is, however, little information available about sample size requirements for such phase II trials and rarely enough patients in single studies to make robust estimates. We have formed an international collaborative group to assemble larger datasets and from these have generated sample size tables for MRI-based infarct expansion as the outcome measure.
Methods— Twelve centers from Australia, Europe, and North America contributed data from patients with hemispheric ischemic stroke. Infarct expansion was defined from initial diffusion-weighted images and later fluid-attenuated inversion recover or T2 images. Sample size estimates were calculated from data on infarct expansion ratios treated as dichotomous or continuous variables. A nonparametric approach was used because the distribution of infarct expansion was resistant to all forms of transformation.
Results— As an example, a 20% absolute reduction in infarct expansion ratio (
1), 80% power, and 
=0.05 requires 99 patients in each arm. To achieve an equivalent effect size with a continuous approach requires 61 patients.
Conclusions— These tables will be useful in planning phase II trials of therapy with the use of MRI outcome measures. For positive studies, biologically plausible surrogates such as these may provide a rationale for proceeding to phase III trials.
Key Words: magnetic resonance imaging • neuroprotection • sample size • stroke
This article has been cited by other articles:
 |
|
 |
|
  K. T. Kreiter, S. A. Mayer, G. Howard, V. Knappertz, D. Ilodigwe, M. A. Sloan, and R. L. Macdonald Sample Size Estimates for Clinical Trials of Vasospasm in Subarachnoid Hemorrhage Stroke, July 1, 2009; 40(7): 2362 - 2367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Kidwell, K. R. Lees, K. W. Muir, C. Chen, S. M. Davis, D. A. De Silva, C. J. Weir, S. Starkman, J. R. Alger, J. L. Saver, et al. Results of the MRI Substudy of the Intravenous Magnesium Efficacy in Stroke Trial Stroke, May 1, 2009; 40(5): 1704 - 1709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Whitehead, K. Bolland, E. Valdes-Marquez, A. Lihic, M. Ali, K. Lees, and for the VISTA Collaborators Using Historical Lesion Volume Data in the Design of a New Phase II Clinical Trial in Acute Stroke Stroke, April 1, 2009; 40(4): 1347 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ebinger, S. Christensen, D. A. De Silva, M. W. Parsons, C. R. Levi, K. S. Butcher, C. F. Bladin, P. A. Barber, G. A. Donnan, S. M. Davis, et al. Expediting MRI-Based Proof-of-Concept Stroke Trials Using an Earlier Imaging End Point Stroke, April 1, 2009; 40(4): 1353 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rosso, N. Hevia-Montiel, S. Deltour, E. Bardinet, D. Dormont, S. Crozier, S. Baillet, and Y. Samson Prediction of Infarct Growth Based on Apparent Diffusion Coefficients: Penumbral Assessment without Intravenous Contrast Material Radiology, January 1, 2009; 250(1): 184 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Hermann Review: Future perspectives for brain pharmacotherapies: implications of drug transport processes at the blood--brain barrier Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 167 - 179. [Abstract] [PDF]
|
|
|
|
|
|
P. D. Schellinger and J. B. Fiebach Establishing Final Infarct Volume: Stroke Lesion Evolution Past 30 Days Is Insignificant Stroke, October 1, 2008; 39(10): 2693 - 2694. [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Olivot, M. Mlynash, V. N. Thijs, S. Kemp, M. G. Lansberg, L. Wechsler, G. Schlaug, R. Bammer, M. P. Marks, and G. W. Albers Relationships Between Infarct Growth, Clinical Outcome, and Early Recanalization in Diffusion and Perfusion Imaging for Understanding Stroke Evolution (DEFUSE) Stroke, August 1, 2008; 39(8): 2257 - 2263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ay, E. M. Arsava, M. Vangel, B. Oner, M. Zhu, O. Wu, A. Singhal, W. J. Koroshetz, and A. G. Sorensen Interexaminer Difference in Infarct Volume Measurements on MRI: A Source of Variance in Stroke Research Stroke, April 1, 2008; 39(4): 1171 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Donnan The 2007 Feinberg Lecture: A New Road Map for Neuroprotection Stroke, January 1, 2008; 39(1): 242 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shuaib, K. R. Lees, P. Lyden, J. Grotta, A. Davalos, S. M. Davis, H.-C. Diener, T. Ashwood, W. W. Wasiewski, U. Emeribe, et al. NXY-059 for the Treatment of Acute Ischemic Stroke N. Engl. J. Med., August 9, 2007; 357(6): 562 - 571. [Abstract] [Full Text] [PDF]
|
|